Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs.
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mrd USD) | Schätzung (Mrd USD) | Abweichung |
|---|